• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

28.85 -0.15 (-0.52%)
Streaming Delayed Price Updated: 11:42 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
7 Stocks Due for a Stunning Short Squeeze ↗
August 09, 2022
If you can handle the heat, these ideas could potentially cook up some massive profits. 
Via InvestorPlace
News headline image
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 08, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday ↗
August 09, 2022
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
May 26, 2022
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
May 25, 2022
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
May 24, 2022
On Tuesday, 540 companies set new 52-week lows. 
Via Benzinga
News headline image
Recap: Stoke Therapeutics Q1 Earnings ↗
May 10, 2022
Stoke Therapeutics (NASDAQ:STOK) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Stoke Therapeutics reported... 
Via Benzinga
News headline image
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
May 04, 2022
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
News headline image
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
May 02, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 07, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
March 23, 2022
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the... 
Via Benzinga
News headline image
Recap: Stoke Therapeutics Q4 Earnings ↗
March 10, 2022
Stoke Therapeutics (NASDAQ:STOK) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders ↗
January 10, 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
News headline image
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
January 10, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Touts Early Signs Of Efficacy For Antisense Drug In Dravet Syndrome ↗
December 03, 2021
Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American... 
Via Benzinga
News headline image
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
December 03, 2021
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021 ↗
December 03, 2021
Upgrades Cowen & Co. upgraded the previous rating for Marvell Technology Inc (NASDAQ: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
November 23, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
November 22, 2021
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021 ↗
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap